Debatforum

A.P. Møller - Mærsk A A/S Årsrapport 2022 (kun på engelsk) 8.2.2023 07.58 • GlobeNewswire • Vedhæftet årsrapport 2022 for A.P. Møller - Mærsk A/S (kun på engelsk). Administrerende direktør i A.P. Møller - Mærsk A/S, Vincent Clerc, udtaler: "2022 var et bemærkelsesværdigt år i mere end én forstand. Samtidig med at vi rapporterer de stærkeste resultater i virksomhedens historie, tog vi partnerskaberne med vores kunder til et nyt niveau ved at sikre deres forsyningskæder i en usikker og turbulent tid. Vores ambition om at levere integrerede logistikløsninger og visibilitet i forsyningskæden møder et stort behov hos vores kunder, som efter de seneste turbulente år ser det som et strategisk indsatsområde at gøre forsyningskæden mere robust og bæredygtig. Nu kigger vi ind i et år præget af makroøkonomisk usikkerhed. Vi fastholder et højt tempo i transformationen af Mærsk og et stort fokus på optimering af driften med den fortsatte ambition om at udfolde nye muligheder for vækst." Kontaktpersoner: Head of Investor Relations, Sarah Spray, tlf. +45 3147 4170 Head of Media Relations, Jesper Løv, tlf. +45 6114 1521 Vedhæftede filer https://ml-eu.globenewswire.com/Resource/Download/122d4c52-8868-4828-bb32-7abaefdd928a https://ml-eu.globenewswire.com/Resource/Download/c07f2025-4483-4ac2-a354-f0aecbc3b2b8 https://www.globenewswire.com/NewsRoom/ReleaseNg/401480285 [image: 110236_apm_terminals_1_4_.jpg]

Full year results at the high-end of the guidance - Strong brand drives resilient growth 8.2.2023 07.30 • GlobeNewswire • Financial highlights Full year organic growth ended at 7% (guidance 4-6%) and the EBIT margin at 25.5% (guidance 25-25.5%). Q4 2022 organic growth of 4% (19% vs Q4 2019) comprising of sell-out growth of -1% (negatively impacted by the fire in the European Distribution Center by roughly 1pp) and network expansion of +4%. Brand shows good resilience in macroeconomic uncertainty; US sell-out growth improves sequentially to -7%, Europe resilient at +2% sell-out growth despite some pockets of macro-driven consumer weakness. Gross margin +0.5pp vs Q4 2021, reflecting good discipline despite a heavily promotional external environment. The EBIT margin in Q4 2022 was 32.5%, an increase of 2.8pp vs. Q4 2021 with good cost control. Leverage remains low with NIBD to EBITDA at 0.8x. Pandora has a strong liquidity and funding position. Proposed dividend of DKK 16 per share and a new share buyback program of DKK 2.4 billion until 30 June with an intention to go up to DKK5.0 billion, assuming no material deterioration in the macroeconomic climate. Proposed dividend of DKK 16 per share and a new share buyback program of DKK 2.4 billion until 30 June with an intention to go up to DKK 5.0 billion assuming no material deterioration in the macroeconomic climate. Phoenix strategy highlights Pandora continues to make good progress on its Phoenix strategy; Moments delivered flat sell-out growth vs Q4 2021, underpinning its resilience and position as a leading product category in jewellery. Prices successfully adjusted in Q4 2022 (4% on average) with positive financial impact. Diamonds by Pandora launch in North America tracking as planned. New collections planned for 2023 with further geographical expansion. Pandora reduced total greenhouse gas emissions (scope 1, 2 and 3) by 6% vs. 2019 baseline, on track to halve emissions by 2030. 61% of all silver and gold came from recycled sources, on track towards 100% by 2025. 2023 outlook and current trading Pandora is confident in its ability to adapt to the uncertain environment whilst driving strategic priorities. Initial guidance for 2023 is -3% to +3% organic growth and an EBIT margin around 25%. Current trading in 2023 has been solid with a good, broad-based pick-up in sell-out growth. This is somewhat helped by an easier comparative base due to Omicron and earlier product launches than last year. Nonetheless, Pandora is pleased with the underlying trading which continues in line with Q4 2022. Alexander Lacik, President and CEO of Pandora, says: "We ended 2022 on a high note. Despite the macroeconomic pressure on consumers and COVID-19 headwinds in China, we continue to deliver solid growth vs. pre-pandemic levels. We have started 2023 well, and are confident that the transformation of the brand over the past few years puts Pandora in a good position to manage adversity and emerge stronger. In 2023, we will keep executing on our strategy, take market share, and accelerate network expansion while taking prudent cost actions to protect margins. " DKK million Q4 2022 Q4 2021 FY 2022 FY 2021 FY 2023 guidance Revenue 9,856 9,011 26,463 23,394 Organic growth 4% 10% 7% 23% -3% to 3% Sell-out growth (like-for-like), % -1% 11% 4% 20% Operating profit (EBIT) 3,206 2,678 6,743 5,839 EBIT margin, % 32.5% 29.7% 25.5% 25.0% Around 25% Attachments https://ml-eu.globenewswire.com/Resource/Download/df3ae02d-2b5e-4080-b82a-f7a5d7f2214a https://ml-eu.globenewswire.com/Resource/Download/c3a33353-b3ea-49b9-997a-b7d9d99b499a https://www.globenewswire.com/NewsRoom/ReleaseNg/401480228 [image: 110229_Outside_Store640x427_1_.jpg]

Ugekommentar #79 Regnskaber fra Vestas ' Rockwool ' Matas ' Pandora ' Carlsberg Se med, når Helge Larsen kommenterer flere af ugens interessante regnskaber. Disclaimer: Videoen er ikke en købs- eller salgsanbefaling af aktier https://www.youtube.com/watch?v=cse02Gdj5vw&t=119s

Hvor finder jeg en shortliste over USA aktier?

Der udskrives i øjeblikket 10.000 recepter om dagen/50.000 om ugen. Hvis det alle er nye patienter, så kan det blive helt vildt. På et år løber 50.000 om ugen op til 2.600.000 patienter. Listepris på Wegovy er 1.400 USD for en måneds behandling. Hvis de 2.6 mio patienter starter jævnt over året er de i behandling 6 måneder i gennemsnit. hvis vi gætter på 50% rabat i gennemsnit på listeprisen, så bliver omsætningen: 50% * 1400usd/mnd * 6,95kr/usd * 2.600.000 patienter * 6 mnd/patient = ca. 75 mia kr. 42% af voksne over 20 år er ramt af obesity (BMI > 30): https://www.cdc.gov/nchs/fastats/obesity-overweight.htm Der er lidt over 100 mio voksne i USA med obesity. Men 75 mia kr. i omsætning på Wegovy er et helt vildt target

Pharmivas patent FOAM I godkänns i EU 9.2.2023 11.53 • MFN • Pharmiva AB (publ) meddelar idag att bolaget har beviljats patent för patentfamiljen FOAM I av den europeiska patentmyndigheten EPO (European Patent Organization). Patentet stärker det kommersiella skyddet för bolagets mousse-baserade drug delivery-teknologi Venerol som egenvårdsprodukten Vernivia mot bakteriell vaginos och illaluktande flytningar bygger på. Patentfamiljen FOAM I utgör ett viktigt skydd för Pharmivas drug delivery-teknologi Venerol och är tidigare godkänd på flera viktiga marknader, bland annat i USA. Beskedet från den europeiska patentmyndigheten stärker Pharmivas ställning i pågående partnerförhandlingar om internationell lansering av Vernivia, en receptfri och antibiotikafri egenvårdsbehandling för bakteriell vaginos och illaluktande flytningar. Vernivia vaginal mousse är bolagets första produkt som bygger på teknologin, och med patentet stärks skyddet för både Venerol och Vernivia på den europeiska marknaden. "Även om vi redan har mottagit ett positivt förhandsbesked för patentfamiljen FOAM I i EU faller en viktig pusselbit på plats i och med det slutliga godkännandet. Patentet har betydelse för våra pågående diskussioner med potentiella partners och kommande marknadsintroduktioner av Vernivia ur ett konkurrensperspektiv, såväl som för fortsatt utveckling av nya produkter och läkemedel som bygger på teknologin", säger Anna Linton, vd, Pharmiva. Patent för FOAM I är nu beviljade i EU, USA, Japan, Kina, Ryssland, Sydafrika, Australien, Kanada och Indien. Patentskyddet gäller till och med år 2035. Patentansökningar har dessutom lämnats in i Brasilien, Indonesien, Korea och Hongkong.

North Media ramte nedre ende af egen prognose i 2022 6/2 10:54 North Medias foreløbige regnskabstal for 2022 viser resultater i den nedre ende af den seneste nedjusterede resultatprognose fra den 2. november. Omsætningen landede på 995 mio. kr. sidste år mod ventet 995-1010 mio. kr. Driftsresultatet blev 192 mio. kr. mod ventet 190-200 mio. kr. North Media, der driver portaler og budvirksomhed, måtte se omsætningen i sin budforretning, Last Mile, falde med 6 pct., da høje papirpriser og stigende inflation fik kunder i detailhandelen til at vælge mindre formater og færre tilbudsaviser til udbringning. Inden for Digital Service havde Boligportalen og jobportalen Ofir tocifret vækst, og det samlede forretningsområde øgede omsætningen med 10 pct. og nåede en overskudsgrad på 7,9 pct. Det elektroniske nøglesystem Bekey lykkedes ifølge North Media ikke med at opbygge nye kundegrupper. En ny ledelse af Bekey skal nu forsøge at skabe fundamentet for skalerbarhed og vækst. North Media venter i 2023 en omsætning på 920-975 mio. kr. samt et driftsresultat, EBIT, før særlige poster på 125-160 mio. kr. Tabel over North Medias foreløbige regnskabstal for 2022: Mio. kr. FY 2022 FY 2020 Nettoomsætning 995 1045,4 EBIT før særlige poster 192 240,2 Resultat før skat 388,1 Resultat efter skat 306,8 North Medias forventninger til 2023: Mio. kr. Ved FY 2022 Omsætning 920-975 EBIT før særlige poster 125-160 .\˙ MarketWire [image: 110140_fullsizeoutput_1e2d.jpeg]

Antallet af besøg på ao.dk var stigende i Q4-22 og det ser ud til at fortsætte i januar-23. Især for Brdr Dahl ser det istedet dårligt ud. https://www.similarweb.com/website/ao.dk/vs/sanistaal.com/#traffic https://www.similarweb.com/website/ao.dk/vs/lemu.dk/#traffic https://www.similarweb.com/website/ao.dk/vs/bd.dk/#traffic Også Google Trends peger på et stort og stigende interesse for A&O Johansen. En del er sandsynligvis grundet EA-kunder, men det kan ikke være den eneste årsag, eftersom EA er relativt lille. https://ao.dk/ea #NordensBilligsteAktie #AmazonPåDansk #Separatkloakering

Interim report - 9M 2022/23 8.2.2023 07.58 • GlobeNewswire • Company announcement no. 13 2022/23 Allerød, 8 February 2023 Interim report - 9M 202 2 /2 3 (1 April - 3 1 December 202 2 ) Profitability improved and free cash flow doubled Driven by a record high number of customers, Matas generated a total revenue of DKK 1,396 million in Q3 2022/23 corresponding to a year-on-year increase of 1.3% from DKK 1,378 million in Q3 2021/22. Underlying sales grew 1.2% in the quarter. Gross margin was 44.5% in the quarter which is in line with the long-term trend. EBITDA before special items came to DKK 296 million in Q3 2022/23 compared to DKK 284 million last year, and the EBITDA margin before special items was 21.2% in the quarter against 20.6% last year. Profit for the period amounted to DKK 147 million after tax which is in line with Q3 2021/22. Customer satisfaction maintained the high level reached in Q2 with a Net Promotor Score of 75 on matas.dk and 73 in stores. Matas.dk strengthened its position as the second most frequently used web shop across all retail categories according to the Danish Chamber of Commerce's E-commerce Analysis for 2022. On 31 January 2023, Matas launched its web shops matas.no and matas.se. A tender for Matas Logistics Center was sent out on 1 February 2023. Matas maintains its guidance for the financial year 2022/23, but now expects to reach the upper end of the guided range for EBITDA margin before special items between 17% and 18%. Gregers Wedell-Wedellsborg, CEO of Matas A/S: "The Christmas season was bright and shining in Matas. We served a record number of customers, maintained our high customer satisfaction, and finished the quarter with 16% growth in online sales. The numbers confirm our growth strategy even in a challenging retail environment. Profitability improved, despite rising facility costs, as a result of growth from our house brands and our pick-in-store initiative, which ensures delivery to customers within one hour and lowers fulfilment costs. On the back of good Q3 results, w e expect to reach the uppe r end of our guided EBITDA margin before special items for the financial year 2022/23 . To gain foothold in international markets, we have now opened our award winning web shop in Sweden and Norway. Thereby, we give access to our unique beauty and wellbeing assortment to both Swedish and Norwegian consumers, 20% of whom already know Matas from visits and holidays in Denmark." Key f igures and ratios 2022/23 Q3 2021/22 Q3 2022/23 9M 2021/22 9M Key figures (DKKm) Revenue 1,396.2 1,378.4 3,438.9 3,373.6 Gross profit 620.9 613.7 1,529.9 1,497.7 EBITDA before special items 295.9 283.5 647.4 634.8 Profit for the period after tax 147.3 146.7 263.1 237.2 Free cash flow 382.4 186.1 541.2 266.8 Ratios Revenue growth 1.3% 5.0% 1.9% 5.7% Underlying like-for-like revenue growth 1.2% 2.8% 1.8% 3.4% Gross margin 44.5% 44.5% 44.5% 44.4% EBITDA margin before special items 21.2% 20.6% 18.8% 18.8% Net interest-bearing debt/ EBITDA before special items 1.5 2.1 Q 3 202 2 /2 3 highlights Matas generated a total revenue of DKK 1,396 million in Q3 2022/23 corresponding to a year-on-year increase of 1.3% from DKK 1,378 million in Q3 2021/22 (1.2% revenue increase announced in the trading update). Underlying sales increased by 1.2%. Online sales grew by 15.5% and physical stores reported sales down by 3.4% compared to Q3 last year. Footfall was strong, and the number of transactions increased by 2.3% to 6.8 million, while the average basket size fell by 0.8% to DKK 203 per transaction. Gross profit for Q3 2022/23 amounted to DKK 621 million, up from DKK 614 million in Q3 2021/22. The gross margin was 44.5%, up from 43.0% in Q3 2021/22, when adjusting for the DKK 20 million from the Club Matas VAT case last year. Other external costs amounted to DKK 105 million in Q3 2022/23, up from DKK 98 million in Q3 2021/22. The increase in other external costs by DKK 7 million was primarily driven by an increase in facility and freight costs compared to Q3 2021/22. EBITDA before special items came to DKK 296 million resulting in an EBITDA margin before special items of 21.2%. The total amortization, depreciation and impairment charges were down by DKK 13 million to DKK 95 million in Q3 2022/23. Profit for the period amounted to DKK 147 million after tax which is in line with Q3 2021/22. Free cash flow was an inflow of DKK 382 million, compared with an inflow of DKK 186 million the year before. 9M 2022/23 highlights Retail revenue was up by 2.0% to DKK 3,365 million. Mass Beauty grew by 4.9%, Health and Wellbeing grew 2.7% while High-End Beauty was in line with last year. Total revenue was up by 1.9% in 9M 2022/23 driven by online growth of 9.3%, while wholesale sales grew 1.1% and physical stores declined by 0.5%. Footfall was strong, and the number of transactions increased by 4.3% to 17.7 million, while the average basket size fell by 2.2% to DKK 191 per transaction. Gross profit for 9M 2022/23 amounted to DKK 1,530 million compared to DKK 1,498 million in 9M 2021/22. The gross margin was 44.5%, up from 43.8%, when adjusting for special items. Other external costs amounted to DKK 269 million in 9M 2022/23, up from DKK 236 million in 9M 2021/22. The higher other external costs were driven by a DKK 12 million increase in energy costs and costs attributable to the online growth in 9M 2022/23. EBITDA before special items amounted to DKK 647 million in 9M 2022/23 compared to DKK 635 million in 9M 2021/22. The EBITDA margin before special items was 18.8% which is in line with last year. Cash generated from operations was an inflow of DKK 757 million in 9M 2022/23 against an inflow of DKK 537 million in 9M 2021/22. Free cash flow was an inflow of DKK 541 million, compared with an inflow of DKK 267 million in 9M 2021/22. Video conference Matas will host a video conference for investors and analysts on Wednesday, 8 February at 10:00 a.m. CET. The video conference and the presentation can be accessed from Matas' investor website: https://investor.matas.dk. Video conference access numbers for investors and analysts: DK: +45 78 76 84 90 UK: +44 203 769 6819 US: +1 646 787 0157 PIN for all countries: 915912 Link to webcast: https://streams.eventcdn.net/matas/q3-interimreport/ Contacts Gregers Wedell-Wedellsborg CEO, phone +45 48 16 55 55 Per Johannesen Madsen CFO, phone +45 48 16 55 55 Klaus Fridorf Head of Communication, phone +45 61 20 19 97 Frederikke Linde Head of Investor Relations, phone +45 60 62 60 87 Forward-looking statements This interim report contains statements relating to the future, including statements regarding Matas Group's future operating results, financial position, cash flows, business strategy and future targets. Such statements are based on Management's reasonable expectations and forecasts at the time of release of this report. Forward-looking statements are subject to risks and uncertainties and a number of other factors, many of which are beyond Matas Group's control. This may have the effect that actual results may differ significantly from the expectations expressed in the report. Without being exhaustive, such factors include general economic and commercial factors, including market and competitive conditions, supplier issues and financial and regulatory issues as well as any effects of healthcare measures that are not specifically mentioned above. Attachment https://ml-eu.globenewswire.com/Resource/Download/7d49cb80-6e1a-44cc-b8ce-93918b639e70 https://www.globenewswire.com/NewsRoom/ReleaseNg/401480288

Kommentar fra Per Hansen, Investeringsøkonom, Nordnet AMBU har leveret et regnskab, som er markant bedre end ventet. Noget kunne tyde på, at AMBU har leveret sin seneste nedjustering i en overskuelig tid AMBUs regnskab er noget bedre end ventet Omsætningen på 1132 mio. er 19 mio. bedre end de ventede 1113 EBIT før særlige poster på 68 mio. er væsentlig over de ventede 15 mio. Omkostningstiltag begynder at virke E BIT marginen på 6 % er ca. 4x af forventningerne Bruttomarginen for kvartalet på 58,5 % ligger 3,1 % point over forventningerne AMBU fastholder forventningerne til helåret Enlig svale gør ingen sommer, men opjustering senere mulig AMBU har leveret alt for mange nedjusteringer siden strategiskiftet i 2019. Deres guidance var lagt til rette på noget som kunne indfris og overgås selv i nærmest et worst case scenario. Udgangspunktet var med andre ord taknemmeligt. Alligevel er dagens regnskab positivt og opløftende. Der er endnu lang vej til en tilfredsstillende vækst og indtjening, men det går den rette vej. Når AMBU i dag fastholder sine forventninger og ikke løfter dem, er det for at undgå, at de senere, hvis noget uforudset skulle indtræffe, bliver tvunget til at nedjustere igen. Året er stadig meget ungt og usikkerheden stor. Opjustering kan komme senere på året. [image: 110163_HQ_building_imagebank_low_2_.jpg]

Kommentar fra Per Hansen, Investeringsøkonom, Nordnet Vestas kom med endnu en nedjustering og fremlagde en skuffende guidance for 2023. I betragtning af prissætning og udvikling, ville den "naturlige" kursreaktion være et større fald. Investorer slap dog for en snitter og kursfaldet blev på beskedne 2,67 %. Nød lærer den nøgle kvinde at spinne og nedjusteringer lærer investorerne at trimme forventningerne! Vestas leverede fredag endnu en nedjustering Bedst som investorerne i det mindste håbede, at 2022 ikke kunne blive ringere end den seneste præcisering (minus 5 %) EBITmargin, undergik Vestas igen forventningerne med en minus 8 % EBIT advarsel. 2023 er et nyt år med nye problemer. Garantihensættelser, forsyningskæder, for lave priser, etc. bliver ved med at drille, OG forsyningskæderne vil også være en større udfordring i 2023, er CEO Henrik Andersen efterfølgende citeret for at sige. Det fremgår også af Vestas' guidance, som ganske enkelt tilsiger, at 2023 igen bliver et år uden vækst, og hvor omsætningen - i hvert fald med det som vi ved , forventes at ende på 14,75 mia. EUR (14-15,5). Det var ca. ¾ mia. under konsensus før meddelelsen. Hvis Vestas rammer midtpunktet af egne forventningerne, vil omsætningsudviklingen være sendt 3 år tilbage til 2020. EBIT marginen forventes at lande mellem minus 2 og plus 3 %. Midtpunktet er minus 0,5 %. Hvis Vestas kan ramme 3 %, svarer det til konsensus før regnskabet på 2,96 %. Det gode spørgsmål er om ikke et "best case" er "mindst sandsynligt efter alt for mange skuffelser og overraskende store vedblivende udfordringer? Bemærkelsesværdig aktie status quo Aktien startede med et større fald på 7 %, men det hele endte i fred og fordragelighed med blot et fald på 2,7 %. Det er billigt sluppet. Her er nogle nedslag pro et contra: Vestas leverede ny skuffelse 2023 bliver forhåbentlig meget bedre end katastrofeåret 2022, men godt bliver det ikke Vestas peger på nye udfordringer med hensættelser på Offshore vind. Det er noget af det som Siemens Gamesa også har været udfordret med. "Cash flowet var stærkt, og sandsynligheden/risikoen for at Vestas skal hente nye penge er faldet", hørte jeg en optimist sige. Korrekt med cash flow, som er relateret til ordreindgangen, men jeg tror ikke generelt investorerne var nervøse for en kapitaludvidelse? Vi fik ikke alle men udvalgte tal, og på baggrund af den samlede EBIT margin på minus 8; en margin på service forretningen på 21,4 % og med udgangspunkt i at serviceforretningen udgør 3,155/14,486 = 21,77 % af Vestas omsætningen, estimerer jeg at Vestas' EBIT margin ved at producere møllerne var -12,66 %. Rasmus Modsat: Hvis aktien ikke falder på skuffelser, er det et styrkesignal Tallene var skuffende uanset hvordan man vender og drejer dem. "Alting bliver bedre i 2024 og i 2025 skal den langsigtede målsætning om 10 % EBITmargin indfris", tænker mange. Det kan meget vel være det sker, men det er også muligt det ikke gør det i det omfang, som investorerne håber. Kursudviklingen giver indtryk af, at om ikke alt, så mange dårligdomme er indpriset, og det herfra kun kan gå fremad, når investorerne ikke reagerer på dårlige tal og nyheder. Tiden vil vise, om den Rasmus Modsat logik passer. Det handler for mig ikke kun om aktien går lavere, men reelt også om risikoen ved at være investeret de kommende kvartaler er større end mulighederne i aktien og i markedet generelt? [image: 109911_20_126_vestas_sprogoe.jpg.coredownload.inline_4_.jpeg]

Kommentar fra Per Hansen, Investerngsøkonom, Nordnet Demant har sine udfordringer, men det som står tilbage efter dagens regnskab er den stærke guidance for 2023, som ligger godt og vel 200 mio. over forventningerne Demant har i 2. halvår leveret et regnskabssæt som skifter lidt mellem bedre end og lidt under forventningerne Kommunikation (headset) var som forventet svag Overordnet er 2022 som forventet +/- 2023 guidance om en vækst på 3-7 % (5 i midten) er noget over konsensus på 3,6 % EBIT guidance på 3,8 (3,6-4,0) er lidt mere end 200 mio. bedre end ventet Produktlanceringer og forventninger om vækst i kommunikationssegmentet ud fra et meget lavt udgangspunktet skal bl.a. drive væksten Stærk guidance giver kursstigning Demant har leveret et fornuftigt regnskab med en stærk guidance, som aktien burde stige på. Spill-over til GN Store Nord: Headset markedet er svagt i Q4. Det vidste eller burde alle vide. Hvis Q4 var lavpunktet her, kan selv et svagt tal fra Demant næppe forurolige GN Store Nord investorerne, som har været så gruelig meget igennem, yderligere

Financial statement as at 31 December 2022 7.2.2023 07:56:54 CET ' Carlsberg A/S ' Financial Statement Release Strong results in a challenging environment Unless otherwise stated, comments and figures refer to full-year performance of the continuing operations. From 1 January 2022, the Russian business is presented as held for sale. 2021 figures have been restated according to IFRS. STRONG VOLUME GROWTH, PARTICULARLY IN ASIA Organic volume growth 5.7% Organic volume development in Western Europe +5.4%, Asia +10.3% and Central & Eastern Europe -0.1% (excluding Ukraine +4.9%). Volume growth of international premium brands: Carlsberg +14%, Tuborg 9%, Grimbergen +11% and Somersby +1%. 1664 Blanc -4% impacted by lower volumes in Ukraine and China. Alcohol-free brews in Western Europe +7%; total alcohol-free brews excluding Ukraine +1%. STRONG REVENUE GROWTH, DRIVEN BY ALL REGIONS Organic revenue growth 15.6% Reported revenue growth of 16.9% to DKK 70,265m. Revenue/hl +9%, with strong growth in all regions. VERY STRONG OPERATING PROFIT AND CASH PERFORMANCE Organic operating profit growth 12.2% Operating profit growth reflecting on-trade recovery in Western Europe and strong Asia performance, particularly in H1, partly offset by higher commodity prices and energy costs. Reported operating profit growth of 13.2% to DKK 11,470m. Operating margin 16.3%. Reported net profit of DKK -1,063m, impacted by write-downs of DKK 10,735m. Adjusted net profit increase of 39.6% to DKK 9,694m. Adjusted earnings per share increase of 43.6% to DKK 69.3. For continuing operations, increase of 23.9% to DKK 55.7. Free cash flow DKK 9,884m. DRIVING SHAREHOLDER VALUE Total share buy-back and dividend payment for the year of DKK 7.8bn NIBD/EBITDA 1.23x (2021: 1.37x). ROIC improvement of 270bp to 15.2%; excluding goodwill +800bp to 41.6%. The Supervisory Board will propose to the Annual General Meeting a 13% increase in dividend to DKK 27 per share, equal to a total dividend payout of DKK 3.7bn. On 27 January 2023, the Group concluded the 2022 DKK 4.5bn share buy-back programme. 2023 EARNINGS EXPECTATIONS 2023 will be another challenging year. Due to our and our suppliers' rolling hedging, last year's commodity and energy price increases will have a significant impact on our 2023 cost of sales and logistics costs. We intend to offset the higher costs in absolute terms through pricing, mix and continued tight focus on costs. While beer historically has been a resilient consumer category, the higher prices in combination with generally high inflation may have a negative impact on beer consumption in some of our markets, particularly in Europe. The development of the war in Ukraine and the impact on our business remain highly uncertain, as is the COVID-19 recovery in China, including consumer off-take during the Chinese New Year celebrations. The wide guidance range reflects these significant uncertainties for 2023. Consequently, 2023 guidance is: Organic operating profit development of -5% to +5%. Based on the currency spot rates at 6 February, we assume a translation impact of around DKK -550m for the full year. CEO Cees 't Hart says: "The Group delivered a strong set of results for 2022 thanks to an impressive effort by our employees across the Group and continued good execution of our strategy. The high earnings and very strong cash generation were achieved despite many challenges, including the war in Ukraine, rising energy and commodity prices, and the impact from the pandemic, particularly in Asia. "Throughout the year, a key priority was the safety and well-being of our Ukrainian colleagues, whose resilience, courage and strength have impressed us deeply. "2023 will be another challenging year, but the strategic, organisational and financial health of our company is strong, and we are confident that our purpose-led and performance-driven culture will drive continued sustainable long-term value creation. "SAIL'22 has successfully guided our journey since 2016. Setting sail for the next five years, our new strategy, SAIL'27, continues the ambitious long-term strategic direction for the Group. As part of SAIL'27, our enhanced ESG programme, Together Towards ZERO and Beyond, sets ambitious milestones for 2030 and 2040." Contacts Investor Relations: Peter Kondrup +45 2219 1221 Iben Steiness +45 2088 1232 Media Relations: Tanja Frederiksen +45 5195 7778 For more news, follow Carlsberg Group on LinkedIn or sign up at www.carlsberggroup.com/subscribe. The results will be presented at a conference call today at 9.30 a.m. CET. Dial-in information and a slide deck will be available on www.carlsberggroup.com.

Har opdateret mit "Genmab Anker 18% skema" som indeholder købs og salgs ideer samt et fremtidssikret kombi forslag. Kombi % er individuel og afhængig af ens risk profil. De 80/20 er mit personlige mix. [image: 107738_Skaermbillede_2022_11_11_120912_Opdateret_skema.jpg]

Efter en turbolent krypto start ser det ud til der endelig er en bundvending at spore for CCD at. Concordiums token/aktien CCD er steget ca. 115% fra bunden i 0.0062 og vi har som det kan ses på dagkortet en højere høj. Der er sket meget på Concordiums blockchain det sidste års tid og det kan man læse mere om her https://concordium.com/ Der kommer en opdatering fra ledelsen imo kl 15.00 og her er link hvis man vil lytte med http://t.me/concordium_official Concordium nu no. 275 på https://coinmarketcap.com/currencies/concordium/ Hvis du gerne vil vide, hvor du kan købe Concordium til den aktuelle kurs, er de bedste kryptovalutabørser til handel med Concordium-aktier i øjeblikket KuCoin, MEXC, Bitfinex, AscendEX (BitMax) og BitGlobal. Jeg benytter selv Bitfinex. Krypto investering er high risk på lige fod med web 3, biotech m.m så man skal træde varsomt. Har selv en passende stake i Concordium som svare til 2% af min portefølje. [image: 109912_CCDUSD_2023_01_30_12_40_41_ccd.png]

Pfizer (PFE) Pfizer er vinderen inden for forebyggelse og behandling af corona. Over halvdelen af omsætningen i 2022 kommer fra vaccine og kur mod corona. Nøgletallene er imponerende. 31% af salget ryger ned på bundlinjen. Oms/oversk: 100 mia/ 31 mia USD MCAP/PE: 251 mia / 8 kurs/ant.akt: 44 / 5,7 mia Johnson & Johnson (JNJ) JNJ er den store gamle inden for pharma. Størst omsætning kommer fra produkter til immun- og cancerbehandling. Man skal være opmærksom på, at kun lidt over halvdelen af omsætningen er egentlig pharma. Resten er beslægtede produkter. Hudcreme, kontaktlinser osv. kan være nyttige og indtægtsgivende; men det er ikke pharma. JNJ fik godkendt en corona vaccine, men tabte konkurrencen på både virkning og bivirkninger. Oms/oversk: 95 mia ( 53 mia pharma) / 18 mia USD MCAP/PE: 424 mia / 24 kurs/ant.akt: 163 / 2,6 mia Pfizer vinder klart over JNJ på nøgletal. Også selv om man indregner et fremtidigt reduceret corona marked.

Kommentar fra Per Hansen, Investeringsøkonom, Nordnet Apple leverede et skuffende kvartalsregnskab. Der er gode forklaringer på hvorfor det går som det går, men skuffelsen kan man ikke komme uden om. Investorreaktion var mild Apple leverede et skuffende 1. kvartalsregnskab i den vigtige periode med julesalg. Iphones salget var 8 % lavere end i tilsvarende periode sidste år. Det er mange år siden jeg kan mindes en så negativ udvikling EPS på 1,88 USD var lidt under det forventede 1,94 Omsætningen var med 117 mia. USD ca. 4 mia. under de forventede 121 mia. De primære årsager til svagheden var 1)USD styrkelsen, 2)produktionsudfordringer i Kina med Iphone 14 og 14 Pro samt 3)Svagere vækstforvetninger Apple giver ingen guidance for indeværende kvartal, men det blev nævnt, at det er sandsynligt med en tilsvarende tilbagegang i omsætning i forhold til samme periode sidste år (ca. 5 %). Moderat kursreaktion på skuffende regnskab I Danmark har vi Novo Nordisk. I USA er der ingen over Apple. Efter det skuffende regnskab faldt Apple med 3,22 % i eftermarkedet. Det er alt i alt en moderat kursreaktion. Tallene var skuffende. Måske tænker investorerne på, at med den USD svækkelse som vi har et set de seneste 4 måneder på nær 15 %, vil indeværende kvartal også blive præget af den stærke USD fra 2022, men så forsvinder den modvind gradvist. Apple kan ikke løbe fra den økonomisk afmatning, som formentlig også kommer til at blive en betydelig faktor også de kommende kvartaler

Vi overvejer om børneopsparing, der har næsten 21 års horisont - bør placeres i fx global index - eller solide enkelt-aktier. Kunne være 50% Novo Nordisk eller mest muligt tilladte i denne. Spørgsmålet er selvfølgelig om Novo Nordisk kan fortsætte med ca. 20% årligt afkast inkl udbytter de næste 21 år. Uanset hvor godt et enkelt selskab kan være - er der høj risiko ved at have 50% eller mere i ét selskab. Hvad er jeres tanker? Hvad ville I gøre? Tænker fedme-medicin bliver kæmpe stort også ude i fremtiden.

Charlie Munger (Vice Chairman of Berkshire Hathaway) has been Warren Buffett's right hand man for decades. But what a lot of people fail to realise is that he's quite a successful investor in his own right. So with high inflation and rising interest rates affecting stock markets globally, let's listen to Charlie's advice on investing in 2023 to make the most of the potential recession and stock market crash. https://www.youtube.com/watch?v=jbxaUpJTb2M

Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 177.0 billion in 2022 Financial report for the period 1 January 2022 to 31 December 2022 1 February 2023 Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 177.0 billion in 2022 Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates (CER) to DKK 74.8 billion. Sales in North America Operations increased by 35% in Danish kroner (21% at CER), and sales in International Operations increased by 17% in Danish kroner (13% at CER). Sales within Diabetes and Obesity care increased by 29% in Danish kroner to DKK 156.4 billion (19% at CER), mainly driven by GLP-1 diabetes sales growth of 56% in Danish kroner (42% at CER). Rare disease sales increased by 7% measured in Danish kroner (1% at CER). Obesity care sales grew by 101% in Danish Kroner (84% at CER). All Wegovy dose strengths were made available again in the US in December 2022. Within R&D, Novo Nordisk initiated two phase 1 trials in NASH based on the siRNA technology platform. For the 2023 outlook, both sales and operating profit growth are expected to be 13-19% at CER. Sales and operating profit growth reported in Danish kroner are expected to be 4 and 5 percentage points lower than at CER, respectively. At the Annual General Meeting on 23 March 2023, the Board of Directors will propose a final dividend of DKK 8.15 for 2022 per share. The expected total dividend for 2022 is DKK 12.40 per share, of which DKK 4.25 was paid as interim dividend in August 2022. The Board of Directors has decided to initiate a new 12-month share repurchase programme of up to DKK 28 billion. PROFIT AND LOSS 2022 2021 Growth as reported Growth at CER* DKK million Net sales 176,954 140,800 26% 16% Operating profit 74,809 58,644 28% 15% Net profit 55,525 47,757 16% N/A Diluted earnings per share (in DKK) 24.44 20.74 18% N/A CER: Constant exchange rates (average 2021). Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. We continued to make progress on our Strategic aspirations and in 2023, we will continue our focus on strong commercial execution, expanding and progressing our innovative pipeline and investing significantly in the expansion of production capacity for current and future portfolio." On 1 February 2023 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors'. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTu [image: 109966_cq5dam.web.2000.2000__5__3_.jpeg]